NovaBiotics Ltd
https://novabiotics.co.uk/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From NovaBiotics Ltd
Deal Watch: Astellas/Cytokinetics Extend Partnership, Make Progress On SMA Candidate
The two firms hope improvement in the six-minute walk test might be accepted by the US FDA as registrational endpoint for reldesemtiv in spinal muscular atrophy. Blackstone acquires Clarus, while Merck licenses TriNKETs from Dragonfly.
Cystic Fibrosis: NovaBiotics Advances Old Dog With New Tricks
Lynovex, a reformulated version of a molecule which has been around for decades for a rare metabolic disease, has just succeeded in a Phase IIb study to treat exacerbations in cystic fibrosis. The mutation-agnostic therapy could improve on current treatments for breakthrough exacerbations, and reduce the associated long-term damaged.
Pipeline Watch: Phase III Starts For CCX168, ETC-1002 And COR-003
Pipeline Watch has been updated to bring greater depth and detail to a potential therapeutic product’s progress through the R&D pipeline. The table brings you a snapshot of selected late-stage clinical trial events in the pharma and biotech industries.
Venture Funding Deals, February 2015
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Venture Funding Deals column provides a monthly review of emerging In Vitro Diagnostic, Medical Device, and Pharmaceutical companies that have received venture funding. This month’s column covers deals announced December 2014 through January 2015.
Company Information
- Industry
- Biotechnology
-
Pharmaceuticals
-
Drug Delivery
- Topical Delivery
-
Drug Delivery
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice